Form D · Biotechnology
MetaStat, Inc.
Boston, MA · CIK 0001404943
Offering snapshot reported Apr 11, 2018 · SEC filing
- Reported sold
- $3.38M Offering amount: $3.63M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 30, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 11, 2018 | Initial | $3,378,928 | No comparison | 6 | SEC filing |
| Jul 5, 2017 | Initial | $2,141,001 | No comparison | 14 | SEC filing |
| Sep 14, 2016 | Initial | $87,500 | No comparison | 1 | SEC filing |
| Jun 10, 2016 | Initial | $495,000 | No comparison | 11 | SEC filing |
| Feb 22, 2016 | Initial | $350,000 | No comparison | 4 | SEC filing |
| Aug 14, 2015 | Initial | $1,200,000 | No comparison | 1 | SEC filing |
| Jan 15, 2015 | Initial | $1,257,500 | No comparison | 5 | SEC filing |
| Oct 31, 2014 | Initial | $0 | No comparison | 1 | SEC filing |
| Oct 31, 2014 | Initial | $280,693 | No comparison | 1 | SEC filing |
| Jul 8, 2014 | Initial | $5,735,427 | No comparison | 40 | SEC filing |
| Jun 20, 2014 | Initial | $215,000 | No comparison | 6 | SEC filing |
| Mar 26, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 24, 2014 | Initial | $650,000 | No comparison | 5 | SEC filing |
| Dec 24, 2013 | Initial | $500,000 | No comparison | 3 | SEC filing |
| Dec 24, 2013 | Initial | $1,487,000 | No comparison | 22 | SEC filing |
| May 11, 2012 | Initial | $880,000 | No comparison | 13 | SEC filing |
| Mar 9, 2012 | Initial | $675,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $100K
- Finders' fees
- $0
- Form D file number
- 021-309940
$2,128,927 of the total offering amount was paid through the exchange of certain securities into the offering. The offering has closed.
In addition to the sales commission noted above, the placement agent also received an aggregate of 86,957 placement agent warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| COVA Capital Partners, LLC | 109761 |
Source: Form D, filed Apr 11, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard J. Berman | Director |
| Paul A. Billings | Director |
| Oscar L. Bronsther | Director |
| Martin J. Driscoll | Director |
| David M. Epstein | Director |
| H. Philip A. Goodeve | Director |
| Douglas A. Hamilton | Director, Executive |
| Harvey Judkowitz | Director |
| Warren C. Lau | Director, Executive |
| Patrick Mooney | Director |
| Daniel H. Schneiderman | Executive |
| David N. Siegel | Director |
| Johan (Thjis) Spoor | Director |
| Johan (Thijs) A. Spoor | Director |
| Johan M. Spoor | Director |
| Jerome B. Zeldis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
27 Drydock Avenue Second Floor
Boston, MA, 02210
Boston, MA, 02210